PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors

• Published in: European journal of pharmaceutical sciences Vol. 41; no. 5; pp. 644 - 649
• Main Authors: Parajó, Yolanda, d’Angelo, Ivana, Horváth, Aniko, Vantus, Tibor, György, Kéri, Welle, Alexander, Garcia-Fuentes, Marcos, Alonso, Maria Jose
• Format: Journal Article
• Language: English
• Published: Kindlington Elsevier B.V 23.12.2010; Elsevier
• Subjects: Angiogenesis; Angiogenesis Inducing Agents - administration & dosage; Angiogenesis Inducing Agents - chemistry; Animals; Biocompatible Materials - chemistry; Biological and medical sciences; Cattle; Cell Line; Chemistry, Pharmaceutical; Delayed-Action Preparations - chemistry; Drug Carriers - chemistry; Drug Delivery Systems; Endothelium, Vascular - drug effects; General pharmacology; Lactic Acid - chemistry; Medical sciences; Microparticles; Nanoparticles; Nanoparticles - chemistry; Neovascularization, Physiologic - drug effects; Particle Size; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; PLGA; Poloxamer; Poloxamer - chemistry; Polyglycolic Acid - chemistry; Synthetic proangiogenic molecule; Tissue Engineering; Nanoparticles; Angiogenesis; Synthetic proangiogenic molecule; PLGA; Tissue engineering; Poloxamer; Microparticles; Pharmaceutical technology; Controlled release form; Nanoparticle; Control release polymer; Vehicle(excipient); Laxative; Glycolic acid polymer; Lactone polymer; Molecules; Lactic acid polymer; Aliphatic polymer; Dosage form; Microparticle; Copolymer
• ISSN: 0928-0987; 1879-0720
• DOI: 10.1016/j.ejps.2010.09.008

Tissue engineering is one of the most promising research areas in bioregenerative medicine. However, the restoration of biological functionalities by implanting bioartificially engineered tissues is still highly limited because of their lack of vascular networks. The use of proangiogenic molecules delivered from a controlled release device is a promising strategy to induce tissue vascularization. Indeed, the controlled release system can enhance the therapeutic effect in vivo of many short half-life drugs, while circumventing the need for repeated administrations. In this work, PLGA:poloxamer blend based micro- and nanoparticles have been developed for the sustained delivery of a recently developed synthetic proangiogenic compound: SHA-2-22. Drug-loaded PLGA:poloxamer blend microparticles were prepared by an oil-in-oil solvent extraction/evaporation technique. Drug-loaded PLGA:poloxamer nanoparticles were prepared by a modified solvent diffusion technique. These drug carriers were characterized with regard to their physicochemical properties, morphology, drug encapsulation efficiency and release kinetics in vitro. The results show that by adjusting the formulation conditions, it is possible to obtain PLGA:poloxamer micro- and nanoparticles with very high drug loadings, and with the capacity to release the active compound in a controlled way for up to one month. In vitro cell assays performed in an endothelial cell model confirmed the bioactivity of SHA-22-2 encapsulated in PLGA:poloxamer microparticles.